Biotechnology

An investor rights law firm is investigating the $929M sale of Theravance Biopharma, asking if shareholders are getting a fair deal or if the board failed them.

As a flesh-eating pest returns to Texas after 60 years, a new partnership signals a shift in biosecurity and San Antonio's ambition as a biotech hub.

Artelo Biosciences advances a novel non-opioid painkiller, using AI to map its effects and potentially revolutionize how we treat chronic pain.

With a new CFO experienced in biotech financing, Tenaya is shoring up its leadership to guide its cardiovascular gene therapies toward pivotal trials.

Evommune halts a key drug trial for chronic hives but leans on a strong cash position and a diversified pipeline to navigate the setback.

4DMT secures a complex $200M credit facility, choosing strategic debt over equity. We dissect the deal and what it signals for late-stage biotech financing.

A new blood test and a powerful partnership between a diagnostics firm and a patient foundation aim to end years of misdiagnosis for a rare lung disease.

A Chinese court cleared Biocytogen’s core antibody platform, a ruling that is less about one patent and more about validating a new era of sovereign innovation.

A new patent for a non-hallucinogenic compound positions Clearmind Medicine to disrupt the multi-billion dollar market for addiction and compulsive disorders.

A new patent in South Korea for a novel breast cancer vaccine offers a potential paradigm shift from treatment to prevention, but the road from patent to patient is long.

BioCryst is closing its discovery labs to save millions, betting on external partnerships for its next big drug. But what is the hidden cost of this pivot?

Relmada Therapeutics joins the Russell 2000, a key validation that opens doors to new capital. But can its high-stakes pipeline deliver on this promise?

With a new FDA Fast Track designation, Satellos Bioscience aims to accelerate its unique muscle-regenerating drug for Duchenne, a strategy that could sidestep genetic limitations.

Larimar Therapeutics is rewriting the rare disease playbook. Its BLA filing for nomlabofusp leverages a novel FDA-aligned endpoint, creating a de-risked path to market.

WideTrial's innovative program hit a major milestone, providing 200 ALS patients with an investigational drug and creating a new model for compassionate use.

Viridian's Lumvoa gains FDA approval for Thyroid Eye Disease, challenging a blockbuster drug and validating DRI Healthcare's unique royalty investment model.

In a major show of biotech investor confidence, Talawar Therapeutics is going public via a SPAC merger, securing $285M to advance its novel bispecific antibody.

A breakthrough oral vaccine from Singaporean scientists promises to end a devastating fish virus, bolstering food security and transforming aquaculture economics.

A German biotech just completed a key trial for a cell therapy that could teach the body to accept a new kidney, freeing patients from a lifetime of harsh drugs.

Positive interim data for a world-first CBD insomnia trial de-risks development, promising a safer alternative to current drugs and igniting global interest.